NCT02793856View on ClinicalTrials.gov

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 26, 2016

Primary Completion Date

August 20, 2018

Study Completion Date

March 17, 2020

Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
DRUG

Cyclophosphamide

To deplete Tregs before collecting peripheral blood

OTHER

PD-1 Knockout T Cells

Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment

Trial Locations (1)

610041

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
collaborator

Chengdu MedGenCell, Co., Ltd.

INDUSTRY

lead

Sichuan University

OTHER

NCT02793856 - PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter